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ABSTRACT 
 
Aim: To find out the prevalence of HPV infection and genotypes in invasive cervical cancer patients.To know the 
predictive and prognostic significance of HPV infection to chemo radiation. Materials and Methods: This  study  
was  conducted  in  the  department  of  radiation oncology in Patients attending to O.P.D during the period of one 
year are included in this study. A total of 145 women age of 30-70 years who were histopathologically proven for 
cervical cancer. All the patients were given radiotherapy. Results: For HPV detection exfoliated cells were  taken  
by direct scrapings  with  cervix brush from  the  cervical tumour before treatment and preserved in preservCyt 
bottles.  The DNP was extracted and was subjected to PCR by using established primers. HPV DNA was detected in 
143 (98.6%) of the patients. Median age of the patients was 50 years. Most of the cases were in stage II disease 
(65.5%). Around 28 different HPV genotypes were found.HPV 16 is the most common genotype (77.6%).34.2% of 
patients were having multiple genotypes.HPV 33, 35, 52, and 58 were found as multiple genotypes and were not 
found in singles. Patients were followed up after chemo radiation.  Mean follow up was 9.6 months and median 
follow up was 12 months.  Only 82 patients remained for follow up at 12 months and the remaining patients did not 
turn up for follow up.   At the end of 12 months, 57 (69.7%) patients were disease free, 11 (13.4 %) were with 
residual disease, and 14 (17.7%) were having recurrences. 20 patients were tested for HPV DNA post treatment; 
HPV DNA was cleared in 20% of patients, and was prevalent in 80% of patients in the study.20% of patients were 
having persistent HPV 16 genotype. All the patients with multiple genotypes prior treatment were found with single 
genotype post treatment.20% of patients were found to have different genotypes post treatment when compared to 
pretreatment.Conclusion: HPV 16 did not show any significance in disease response. 80% of patients had persistent 
HPV DNA post treatment. 
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Introduction
National Cancer Institute refers cancer as to a class 
of disease in which a cell or a group of cells 
divide and replicate uncontrollably, intrude into 
adjacent cells and tissues (invasion)  and  ultimately 
spread  to  other  parts of  the  body other  than  the  
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location at which they arose (metastasis).   Cervical 
cancer refers to proliferation of abnormal cells most 
commonly malignant cells that develop in the tissues 
of the uterine cervix. Worldwide, Cervical cancer is 
the fourth most common cancer in women, and the 
seventh overall, with an estimated 528,000 new 
cases in 2012.   Around 85% of the global burden 
occurs in the less developed regions, where it accounts 
for almost 12% of all female cancers. High-risk 
regions, with estimated ASRs over 30  per 100.000, 
include Eastern Arica (42.7).Melanesia (33.3), 
Southern (31.5) and Western Asia (4.4). Cervical 
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cancer remains the most common cancer in women in 
Eastern and Middle Africa.   There were an 
estimated 266,000 deaths from cervical cancer 
worldwide in 2012, according for 7.5 of all female 
cancer deaths.   Almost nine out of ten (87%) 
cervical cancer deaths occur in the less developed 
regions.  Mortality varies 18-fold between the 
different regions of the world, with ranging from less 
than 2 per 100,000 in Western Asia, Western Europe 
and Australia/New Zealand to more than 20 per 
100,000 in Melanesia (20.6), Middle (22.2) and 
Eastern Africa (GLOBOCAN 2012). India had a 
national program for cancer since 1975, when the 
emphasis was on equipping premier cancer 
institutions, which, by 1984-85, shifted to primary 
prevention and early detection of cancer cases and, by 
1990-91, to the district cancer centres. Strengthening 
of  existing regional cancer centres, development 
of oncology wings  in  medical  college  hospitals,  
the  district  cancer  control  program,  and  the 
decentralized NGO scheme were the priorities of 
the program[1].So far, NCCP has supported 85 
oncology wings in medical colleges including 27 
tertiary cancer centres across the country.  Keeping in 
view the preventable common risk factors of cancer 
and other non-communicable diseases (NCDs), the 
ministry has formulated a National Program for 
prevention and control of cancers, diabetes, 
cardiovascular diseases and stroke (NPCDCS) after 
integrating the NCCP with other NCDs.  The major 
components of this program have been to strengthen 
100 districts in 21 states for cancer care services, 
strengthen 65 centres as tertiary cancer care centres 
(TCCCs) throughout the country. An  analysis  of  
population-based  survey  indicates  that  coverage  of  
cervical cancer screening in developing countries is 
5% compared to 63% in developed countries[2]. Most 
of the cases (85%) are presented in advanced and 
late stages, and more than half (63%-89%) have 
regional disease at the time of presentation 
[3].Cervical cancer diagnosis and treatment in the 
advanced stages makes it a costly exercise, with a 
poor prognosis resulting in poor compliance. Despite 
its high incidence large scale population based studies 
on the HPV prevalence and the genotype distribution 
are very few from this region.   The inconsistency in 
the overall reported prevalence and genotype 
distribution in various Indian studies warrant more 
studies to understand the distribution of HPV in 
different parts of the country.  The reported incidence 
of multiple HPV infection in patients with cervical  
cancer  varies  greatly  and  ranges  between  0%  
and  36%  have been published[4].A recent study 
suggested an average of 3.3 different HPV types in 
each patient with cervical dysplasia[5]. Patients with 
multiple HPV types may have a higher risk  of  
persistent  infection  compared  to  those  with  single  
HPV[6].  Persistent  HPV infection in turn, is 
necessary for the development of cervical cancers[7]. 
Although the standard treatment of locally advanced 
cervical cancer includes radiotherapy, little is known 
about the impact of HPV on the response to 
radiotherapy and on the patients clinical outcome. 
While concurrent chemo radiotherapy is the main 
treatment modality for locally advanced cervical 
cancer, treatment failure in the central pelvis occurs in 
approximately 20-25% of patients
 
in terms of 
radiotherapy outcome, several past studies showed 
that HPV persistence is associated with high rates of 
local recurrence and poor overall survival in patients 
with cervical cancer. Since there is limited data 
available regarding the status of HPV genotypes in 
cervical cancer and its role in predicting and 
prognosticating the disease after treatment in Andhra 
Pradesh.  I envisage undertaking the study to 
estimate the prevalence of high risk group HPV 
genotypes in histologically proven cases of cervical 
cancer (carcinoma cervix) cases and its predictive and 
prognostic significance to the treatment among the 
women attending MNJ Cancer Institute, Hyderabad for 
treatment. The purpose of the study was to determine 
the association between HPV Genotypes and the 
invasive cervical cancer and its role in likelihood of 
response to radiotherapy and survival. 
 
Materials and methods 
 This  study  was  conducted  in  the  department  of  
radiation     oncology,  Mehdi NawabJung Institute of 
oncology & Regional cancer centre at Hyderabad.It 
was a prospective observational cohort study. Patients 
attending to O.P.D in department of radiotherapy in 
this hospital during the period from October 2013 to 
March 2014 are included in this study. A total of 145 
patients who were histopathologically proven for 
cervical cancer were included in the study after taking 
consent from the patient.  All the patients were given 
radiotherapy.  
Inclusion criteria were age of 30-70 years, women 
willing to give consent, women willing to take 
treatment in this hospital, no history of prior 
treatment for CIN or Cervical Cancer, women with 
intact uterus, women with no history of debilitating 
disease or mental illness and women with FIGO stage 
I – stage III.  
Exclusion criteria were women with pregnancy, 
bleeding disorders contraindicating blood sample 
collection, women with stage IV disease, women who 
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had taken radiation to pelvis earlier.Informed consent 
is taken from the women with histopathological 
proven cervical cancers who are willing to take part 
in this study. Pre-treatment evaluation was complete 
history was taken, general and physical examination, 
local examination includes Abdomen, pelvic, rectal 
examination, systemic examination, hematological 
investigations like complete blood picture, renal 
function tests, liver function tests, screening of 
HIV/HBs Ag, biopsy from the primary tumor (edge 
of gross tumor or 4 quadrants), X-ray chest, 
ultrasound abdomen and pelvis. 
 
 
 
Results 
 
 A total  of  188  patients  who  were  
histopathologically proved  to  have  cervical cancer 
were enrolled into the study. But only 145 patients 
satisfied the inclusion and exclusion criteria and were 
included in the study. Reasons for exclusion of the 
patients were treatment with surgery alone, 
unwillingness to take treatment in this hospital.  
Demographics: Median age was 50 (range 30-70 
years). Mean age is 49.26 ± 10.7. 25 patients 
(17.2%) are in 30-39years of age, 39 (26.9%) in 40-
49 years age group, 47(32.4%) in 50-59 years and 34 
(23.4%) are in 60-70 years of age. More than 50% of 
patients were in the age group of 40-60 years. 
 
Graph 1: Distribution of cases according to age 
 
 
Histology: Patients had histopathological diagnosis of squamous carcinoma in 141 patients (97.2%), 
adenocarcinoma in 2 patients (1.37%) and adenosquamous carcinoma in 2 patients (1.37%). Degree of 
differentiation: 132/145 (91%) patients were having well differentiated carcinoma’s, 8 (5.5%) were   
moderately   differentiated   carcinoma, 3   (2.1%)   were   poorly   differentiated carcinoma and2 were (1.1%) 
neuroendocrine differentiation. 
Stage Wise grouping:  
Graph 2: Distribution of cases according to stage 
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Patients were in stage I (n=8;5.5%), stage II 
(n=95;65.5%) and stage III (n=42;29%). More 
number of cases was found in stage II disease.  
HPV infection prevalence: Out of 145 patients only 
2 patients (1.37%) were HPV negative and 143 
patients. Out of 2 HPV negative patients, one did not 
complete the treatment and absconded. One patient 
lost for follow up after completing the treatment.  
Prevalence of different HPV genotypes: 28 
different types of HPV DNA were found in our 
study. Seventeen high risk types (HPV 16, 18, 31, 
33, 35, 39, 45,51, 52, 56, 58, 59, 68, 73, 82, 53, 66) 
and eleven low risk types (HPV 6, 42, 54, 61, 62, 
64, 70, 72, 81, IS39, CP108) were found. All the 
low risk types were found along with high risk type 
and did not occur separately. Out of 143 patients, 
HPV 16was prevalent in 111 (77.6%) patients. 
HPV 18 was found in 15 (10.48%) patients. HPV 
52 in 12 (8.39%) patients, HPV 35 and HPV 58 
in 11 patients (7.69%), HPV 33 in 10 (6.99%) 
patients, HPV 62 in 7 (4.89%) patients, HPV, 31 in 
6 (4.19%) patients, HPV 56,59,53,54 in 5 (3.49%) 
patients, HPV 51, 42, 58 in 4 (2.79%) patients, 
HPV 45,61,58 in 3 (2.09%) patients, HPV 73,83 in 
2 (1.39%) patients, and HPV 39,66,68,6 CP6108 in 
1(0.69%) patients.  
Table 1: Single Vs multiple HPV genotypes and HPV genotype distribution 
HPV Frequency Percent 
Single genotype 94 65.73% 
Multiple genotype 49 34.2% 
Total 143 100.0 
HPV Type Frequency Percent 
HPV 16 76 53.1% 
HPV 18 7 4.9% 
other single types 11 7.7% 
HPV16+Other Types 35 24.4% 
Non HPV 16 (Multiple) 14 9.79% 
Total 143 100 
 
Out of 143 patients 94 (65.73%) patients were 
infected with single type of HPV genotype and 49 
(34.2%) patients were infected with multiple 
genotypes.  
Distribution of cases according to single/multiple 
genotypes: HIV positive patients and HPV: 4/145 
patients were HIV positive.4 (100%) of them had 
multiple HPV genotypes in their cervical smears. All 
of them did not complete the treatment.  
Prevalence of HPV 16 genotypes: Among 143 
patients who were positive for HPV genotypes HPV 
16 were found in 111 (77.6%). HPV 16 as single 
genotype were found in 76 (53.1%) patients and HPV 
16 along with other genotypes were found in 35 
(24.4%) patients.  
HPV 16 among different grades: 104/136 (76.47%) 
patients were found to have HPV 16 as single or in 
multiple genotypes.3/3 (100%) patients who were 
classified as poorly differentiated carcinoma were 
having HPV 16 as a single genotype.2/2 patients with 
neuroendocrine differentiation were having HPV 16, 
one as single genotype and as multiple genotytpe. 
Other genotype HPV 18 were found in 15 (10.4%) 
patients, as single genotype were found in 7 (4.89%), 
and as multiple genotype were found in 8 (5.59%) 
patients. Other single genotypes were found in 11 
(7.69%) patients. Multiple genotypes without HPV 16 
were found in 14 (9.79%).  
HPV 33, 35, 52, 58 genotypes: these genotypes were 
found in (11-12) 8% of patients and all the genotypes 
were found together in multiples and were never found 
in single. 
Table 2: shows single and multiple genotypes among stages. 
Stage Single genotype Multiple genotypes Total 
X
2
 
P 
stage I 7 (4.9%) 1 (0.7%) 8 (5.6%)  
 
 
1.83 
 
 
 
0.4 
Stage II 60 (41.9%) 34 (23.7%) 94 (65.7%) 
stage III 27 (18.9%) 14 (9.8%) 41 (28.6%) 
Total 94(65.7%) 49(34.2%) 143(100%) 
Out of 94  patients  (65.7%),  with  single  
genotypes,  7(4.9%),  60  (41.9%), 27(18.9%) 
patients are present in stage I, stage II, and stage III 
disease. Out of 49 patients with multiple genotypes,1 
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(0.7%), 34(23.7%), 14 (9.8%) are present in stage I, 
stage II, stage III disease. The chi square (χ2) value 
for significance of correlation between single and 
multiple genotypes for FIGO staging was 1.83 and p 
value was 0.400. As the p value being ≥ 0.05, With 
regard to stage at presentation, there was no 
significant difference between single and multiple 
genotypes. 
Table 3:  shows HPV 16 vs non HPV 16 genotypes 
Stage HPV 16 genotype Non HPV 16 genotypes Total 
X
2
 
P 
Stage I 6(5.4%) 2 (5.8%) 8 (5.5%)  
 
 
 
0.49 
 
 
 
 
0.78 
Stage II 72(64.8%) 24 (70.5%) 94 (65.7%) 
Stage III 33 (29.7%) 8 (23.5%) 41 (28.6%) 
Total 111(77.6%) 34(23.7%) 143(100%) 
 
Out of 111 patients with HPV 16, 6 (5.4%), 
72(64.8%), 33(29.7%) patients were found in stage I, 
stage II, stage III disease. Out of 34 patients with 
non HPV genotypes 2(5.8%), 24 (70.5%), 8(23.5%) 
were found in stage I; stage II, stage III disease. The 
chi square (χ2) value for significance of correlation 
between HPV 16 and non HPV 16 genotypes for 
FIGO staging was 0.49 and p value was 0.78. As the 
p value being ≥0.05, With regard to stage at 
presentation, there was no significant difference 
between HPV 16 and non HPV 16 genotypes. 
 Treatment response assessment:139/145 patients 
were planned for chemo radiation and 6/145 patients 
with FIGO IB/IIA underwent surgery followed by 
post op adjuvant radiotherapy. 47/145 (32.4%) 
patients  absconded  in  between  treatment  and  did  
not  turn  up  for  completion  of treatment. Phone 
calls were made to trace the patients. One patient died 
during treatment due to sepsis. Patients were followed 
every 3 months. 
Table 4: shows response assessment at the end of 12 months 
Response at 12 months Frequency Percent 
Locally disease free 57 69.5% 
Residual disease 11 13.4% 
Recurrences 14 17.07% 
Total 82 100% 
 
Patients are followed up every 3 months. Clinical 
history is taken, general examination, local 
examination at each follow up and investigations 
when necessary were done.Out of 97 patients 5 of 
them did not turn up for follow up post treatment 
and 10 of them lost for follow up later. At the end 
of 12 months out of 97patients,15 patients lost for 
follow up. Out of 82 patients 57 (69.51%) patients 
were disease free locally, 11 (13.4%) patients had 
residual disease, 10 (12.1%) patients had local 
recurrence.4 (4.87%) had distant metastasis. 
Table 5: shows disease response in relation to HPV (Single/Multiple): 
Response at 12 months Sin/multiple genotypes Total 
X
2
 
P 
Single Multiple 
Disease free 40 (70.1%) 17 (29.82%) 57 (69.5%)  
 
 
 
 
7.2 
 
 
 
 
 
0.02 
Residual disease 4 (36.3%) 7 (63.6%) 11 (13.4%) 
Recurrence 12 (85.4%) 2 (14.2%) 14 (17%) 
Total 56 (68.2%) 26 (31.7%) 82 (100%) 
Among 57 patients who were locally disease free 
single genotypes were found in 40 (70.1%) and rest 
of 17(29.82%) patients had multiple genotypes. 4/11 
(36.3%) patients with residual disease had single 
genotypes and 7 /11 (63.6%) patients had multiple 
genotypes.12/14 (85.7%) of patients with recurrence 
disease had single genotypes and 2/14 (14.2%) 
patients had multiple genotypes. The chi square (χ2) 
value for significance of correlation between single 
and multiple genotypes for disease response was 7.2 
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and p value was 0.02. As the p value is <0.05, with 
regard disease response, there was significant 
difference between single and multiple genotypes.  
Table 6: Disease response in relation to HPV 
Response at 12 months HPV 16/non HPV 16 Total 
X
2
 
P 
 HPV 16 Non HPV 16 
Disease free 44 (77.1%) 13 (22.8%) 57 (69.5%)  
 
 
 
 
0.1
3 
 
 
 
 
 
0.9 
Residual disease 8 (72.7%) 3 (27.8%) 11 (13.4%) 
Recurrence 11 (78.5%) 3 (21.4%) 14 (17.1%) 
               Total 63 (76.8%) 19 (23.1%) 82 (100%) 
44/57 (77.1%) patients who were locally disease free had HPV 16 genotype and 13/57 (22.8%) patients had non 
HPV 16 genotypes.  8/11 (72.7%) patients with residual disease had HPV 16 genotype and 3/11(27.27%) patients 
had non HPV 16 genotypes.11/14  (78.5%)  patients  with  recurrence  disease  had  HPV  16  and  3/14 (21.4%) 
patients had non HPV 16 genotypes. The chi square (χ2) value for significance of correlation between HPV 16 and 
non HPV 16 genotypes for disease response was 0.13 and p value was 0.9. As the p value being ≥0.05, With regard to 
disease response, there was no significant difference between HPV 16 and non HPV 16 genotypes. 
Table-7: Pretreatment HPV and post-treatment HPV: 
 
 
 
Pretreatment HPV 
Post- treatment HPV at 12 months  
Total HPV cleared Persistent HPV 16 Persistent 
HPV 18 
Other single 
genotypes 
HPV 16 4 5 0 4 13 
HPV 18 0 0 1 0 1 
HPV 16+multiple 
genotypes 
0 1 1 2 4 
Non HPV 16 multiple 
genotypes 
0 0 0 2 2 
Total 4 6 2 8 20 
Mean follow up of the patients was 9.6months and 
median follow up period was 12 months. After 12 
months, 20 patients were screened for post treatment 
HPV prevalence.4/20 (20%) patients cleared HPV 
DNA post treatment.16/20 (80%) patients were having 
HPV in their cervical smears. 6/20 (25%) of them had 
persistent HPV 16 genotype. 6/20 (25%) patients who 
were having multiple genotypes pretreatment, were 
found to have single genotype post treatment. 6/20 
(25%) patients were having different HPV genotypes 
in their smears post treatment which are different from 
pretreatment HPV genotypes. 
 
Discussion 
 
Studies have shown that cervical cancers can occur 
with multiple HPV genotype infections.   The 
incidence of multiple HPV infection is related to the 
method of HPV detection.   In previous reports, the 
rate of multiple HPV infection in invasive cervical  
cancer ranged between 0% and 36 %. Apart from 
ageographical differences, the  differences may be due 
to the type of tumour sample analysed (paraffin-
embedded tumour versus cell samples of a cervical 
brush) and the molecular techniques used for HPV 
detection. Clifford et al reported the prevalence of 
multiple HPV infection with a frequency ranging from 
11.5% in Turin, Italy, to 42.4% in Ho Chi Minh City, 
Vietnam [9]  While Bachtiaryetal.[10] reported that 
multiple HR-HPV infections were seen in 46% of 
cervical cancer biopsies.  In our study, multiple HPV 
infections with at least 2 HPV genotypes are present in 
33.1% patients. This result is consistent with above 
results. Multiple HPV infection was found to be 
associated with persistence of HPV infection that itself 
leads to neoplastic transformation. Impaired  immunity  
might  play  an  important  role  in  multiple  HPV  
infection. Palefskyet. Al[11]demonstrated recently a 
46% prevalence of multiple HPV infection among 
HIV-infected women, whose immune system was 
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seriously compromised, In a further study, the presence 
of multiple infections was strongly associated with 
HPV persistence in HIV infected women.100Thus, 
carriers of multiple HPV types might have  deficient 
immune responses to HPV that predispose them to 
persistent infection.  In the present study 4 of the 
patients were HIV-positive.   All the 4 patients had 
multiple genotypes.  But our number is less to correlate 
with the above study. Bao et al.[12 ]performed a meta-
analysis of HPV genotyping in Asia and reported that 
there were eighteen HPV genotypes detected from 
cervical cancer, of which the 10 commonest HPV 
genotypes were HPV 16, 18, 58, 52, 33, 45, 31, 35, 39 
and 51. Study by Abdul Raub in Malaysia, detected 
HPV 58 (10.7%), 52 (10.4%) and 33 (10.4%) were the 
3 commonest HPV genotypes after HPV 16 and 18.  
This finding is similar to the studies conducted in 
Indonesia, China, Hong Kong, Taiwan, Korea and 
Japan13. Comparing these data with current study 28 
types of HPV genotypes were found. HPV 16 (74.4%), 
18 (10.3%), 33 (6.8%), 35 (7.5%), 52 (8.27%), 58 
(7,5%) were found mostly.  However it is slightly 
different when compared to US and Europe where it 
was reported as HPV 16, 18, 31, 45 and HPV 16, 18, 
33, and 31, respectively (Smith et al.)14. While HPV 
16 and 18 still remain the 2 commonest types across 
the world, other HPV types may differ.   This suggests 
that the distribution of different HPV genotype differs 
in geographic distribution and may be due to ethnic 
diversity. This study is also similar to another study by 
Shilpi Roy15from Karnataka; HPV DNA was detected 
in 63 (88.73%) patients.  With respect to the subtypes, 
out of 63 samples which showed presence of HPV, 46 
samples were positive for HPV 16 (73.01%), 5 
samples were HPV 18 positive (7.93%) and 2 samples 
were positive for both HPV 16 and 18 (3.17%).  10 
samples i.e. 15.87% patients had other oncogenic HPV 
i.e. 31,35,52 and 58 in their study. Study by P. Basu 
from Kolkata in 2010, 16 determined HPV genotype 
distribution in 91/7% of the cases.   Genotype 16 was 
the most common type, detected alone in 59.4% and in 
association with type 18 in 3.6% of cases.  Genotype 
18 was detected as a monotype in 13.3% cases.  In 
total, types 16 and 18 alone or in co-infection with 
each other were detected in 76.3% cases.  Genotype 22 
was the third most common type and overall, but 
genotypes 16, 18, 31, 33 and 45 were the five most 
common types, detected in 87.1% of the total cases 
which is slightly different from our study. This  study  
showed  similar  finding  as  that  of  study  conducted  
by  Soujanya[17] from  Hyderabad which shows    
87.8% of high risk HPV types in cervical cancers and 
among them  HPV  16,  18,  33,  35,  52,  58,  45,  59  
were  found  common.    Pattern  of  HPV distribution 
remained same in this region. One explanation as to 
why these HPV types was a common element of 
multiple infections may be that these HPV types 
usually occurs in combination with phylogenetically 
closely related types (clade A9: HPV 16, 31, 35 and 
58)().  It is possible that these types share 1 or more 
epitopes that render them particularly sensitive to loss 
of immune control. Recently, Liaw et al.[18]  observed 
a reduced risk for subsequent acquisition of a new 
infection within the same phylogenetic clade A9 in 
initially cytological normal women, which implies a 
potential protective cross reactivity within clade A9.  
The immunologic situation, however, is probably 
different in cancer patients and cross-reactivity was 
possible.  Future studies will focus on the role of HPV 
type 33, 35, 52, 58 in multiple HPV infection. In this 
study, type 16 was found to be far the most common, 
with an overall prevalence of 76.5% when taken into 
account both single and multiple infections, and type 
16 and type 18 alone or with combination in 84.8%.  
This is similar to study conducted by P. Basu16 in 
India, who also found overall prevalence of HPV 16 as 
65.5% when taken into both single and multiple 
infections.  Excluding coinfections with other types, 
types 16 and 18 prevalence rate of 78.9% reported in 
the metaanalysis of Indian studies (Neerja et al., 2008), 
and 77% reported by Saranath et al in a separate Indian 
study of 337 cases of invasive cervical cancer[19]. 65-
70% in less developed countries compared to a higher 
prevalence of 74-77% in more developed  
countries[19].  A recent study from France has 
reported types 16, 18 in 82% of cervical cancers, again 
indicating a higher attributable fraction than what is 
generally estimated (Pretet et al., 2008)[20 ].Studies 
from Delhi and Hyderabad also showed high 
prevalence of HPV 16 as 59.37% and 66.7% 
respectively comparatively lesser prevalence than our 
study. As 84.8% of patients were having HPV 16 and 
HPV 18, vaccination with the vaccines which are 
available now, (quadrivalent and nonavalent) would 
decrease these infections which are the main 
contributors for cervical cancers and as a result burden 
of the disease would decrease. To date, information is 
not available concerning the natural history of HPV 
infection in cervical carcinoma managed with RT[21]. 
The role of HPV infection in the oncogenesis of cancer 
of the uterine cervix is well established. Riou et al. 
Reported that HPV is a prognostic factor for better 
clinical outcome when compared to non HPV 
patients[22].  Most previous studies examined HPV 
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infection only before RT.   They assessed a possible 
correlation between a pre-treatment status of HPV 
infection (HPV DNA-positive/negative tumour) and 
prognosis in patients treated with RT[21].  
Harima et al. found that HPV-negative patients had a 
highly significant shorter survival than the HPV-
positive group.  The status of p53 (58 out of 65 had a 
wild-type p53 gene) was only of borderline  
significance for clinical outcome,  and  HPV  status 
remained significant in the multivariate analysis.  
Several studies reported a decreased rate of p53  
mutations among HPV-positivetumours, and HPV-
positive tumours appear to express significant  
amounts  of  functional  (wild)  p53,  which  may  
contribute  to  the  cellular response to radiation 
therapy.21 Lindel et al.investigated HPV status and E2 
gene integrity as potential prognostic parameters for 
clinical outcome and prediction of RT response in 40 
women with locally advanced cervical cancer treated 
with curative RT.  Their study revealed that HPV is an 
independent prognostic parameter for outcome and 
radiation response.  In their study, they  confirmed  a  
trend  for  a  better  clinical  outcome  for  women  with  
HPV-positive cervical cancer with an intact E2 gene.   
By the fact that E2 protein is able to induce apoptosis 
independent of other viral proteins,      it might be 
possible to use it as an antitumor agent not only in 
HPV-positive cancers.   They concluded that exact 
relationship  between  HPV  genes  and  response  to  
radiation  has  to  be  further investigated to classify a 
special group of cancers not only in the uterine 
cervix[23]. Nagai et al. Reported the first study in 
which HPV infection status was examined before, 
during, and after RT.   Their data demonstrated that, in 
HPV DNA-positive cervical carcinoma, persistence of 
HPV DNA in the cervix at the end of RT was highly 
predictive of local recurrence.  In their study, sampling 
for HPV DNA examination was performed every 2-4 
weeks during RT and every 3 months after RT.  They 
found that cervical HPV DNA cleared in 42 patients 
(43.3%) and persisted in 55 patients (56.7%) at the end 
of RT.   Moreover, multivariate statistical analysis 
showed that persistence of HPV DNA represented an 
independent and the most powerful prognostic 
factor24. In conclusion, the excellent clinical 
performance of the combination strategy with HPV 
genotyping and cytology is considered a powerful tool 
for managing the post-treatment follow-up. In our 
study we could not evaluate post treatment HPV 
prevalence in all 82 patients during follow up due to 
social reasons and financial constraints. Due to the 
constraints in the size of our study post treatment, it 
was not possible to test the significance of the post 
treatment HPV prevalence.  Large scale studies will 
provide newer insights, to formulate better methods to 
meet the future challenges for cervical cancer  
prevention our  efforts  will  also  continue  for  
assessing  the  response  to  the treatment. The 
development of HPV vaccines holds tremendous 
promise for developing countries Like India, where 
cervical cancer is the most common malignancy 
among middle aged women, particularly in rural areas.  
The availability of HPV vaccine will not only help in 
curbing the cervical cancer incidence and mortality, 
but it may also bring down the cost burden of the 
cervical cancer screening programmes. 
  
Conclusion 
 
 HPV was prevalent in 98.6% of patients.More number 
of patients with multiple genotypes was found. HPV 
16 was more prevalent among different genotypes. 
Single and multiple HPV genotypes play significant 
role in disease response.HPV 16 did not show any 
significance in disease response. 80% of patients had 
persistent HPV DNA post treatment.
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